공시 • Jan 19
Adhera Therapeutics, Inc. Announces the Resignation of Zahed Subhan as Chief Executive Officer On January 12, 2024, Adhera Therapeutics, Inc. received notice from Zahed Subhan that he was resigning as the company’s Chief Executive Officer and as a member of the Board of Directors. Mr. Subhan’s decision to resign as Chief Executive Officer and member of the company’s Board of Directors was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices. 공시 • Jan 18
Adhera Therapeutics, Inc. Announces Board Resignations On January 9, 2024, Adhera Therapeutics, Inc. received notice from Trond K. Waerness that he was resigning from Board of Directors effective January 12, 2024. Mr. Waerness’ decision to resign as director was not the result of any disagreement with the company on any matter relating to the Company’s operations, policies, or practices. Further, on January 12, 2024, the company received notice from Zahed Subhan that he was resigning as the company’s Chief Executive Officer and as a member of the Company’s Board of Directors. Mr. Subhan’s decision to resign as Chief Executive Officer and member of the Company’s Board of Directors was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices. 공시 • Nov 17
Adhera Therapeutics, Inc. announced delayed 10-Q filing On 11/15/2023, Adhera Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. 공시 • Aug 17
Adhera Therapeutics, Inc. announced delayed 10-Q filing On 08/15/2023, Adhera Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. 공시 • May 16
Adhera Therapeutics, Inc. announced delayed 10-Q filing On 05/15/2023, Adhera Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. 공시 • Jan 26
Adhera Therapeutics to Collaborate with Alberta Diabetes Institute, University of Alberta to Initiate Clinical Trial of MLR-1023 in Type 1 Diabetes Adhera Therapeutics, Inc. announced that the company is to commence a dose finding study of MLR-1023 (tolimidone) in Type 1 Diabetes in collaboration with the Alberta Diabetes Institute (ADI) at the University of Alberta (U of A), located in Edmonton, Alberta, Canada. The company and U of A are finalizing the details of the trial, which are expected to be released shortly. The results of the study will also be utilized to optimize the dose range used in Adhera’s forthcoming Phase 2 multi-center clinical trial of MLR-1023 in Type 1 Diabetes. It is anticipated that the ADI will also participate in the multi-center study. MLR-1023, a lyn kinase activator with potent beta cell proliferation activity, has demonstrated exceptional clinical safety and tolerability in over 700 patients in Phase 2a and Phase 2b Type 2 diabetes studies. Adhera will focus its initial clinical trials on patients with Type 1 Diabetes where the Company can benefit from several factors, including the existing safety profile, which is expected to undergird the drug candidate moving directly into Phase 2 clinical trials and a shorter and less expensive clinical pathway compared to Type 2 Diabetes. Independent research has demonstrated robust therapeutic effects of MLR-1023 in Type 1 Diabetes preclinical models. There is a large addressable market due to the lack of alternative treatment options in Type 1 Diabetes aside from insulin injections or an insulin pump. In Type 1 Diabetes patients, the pancreas produces little to no insulin. At a cellular level, the immune system attacks pancreatic beta cells that produce insulin, leaving the patient with deficient levels of insulin to control blood glucose and a resulting dependency on exogenous insulin. Approximately 20%-30% of Type 1 Diabetes patients have demonstratable amounts of beta cell mass as determined by detectable amount of the insulin synthesis byproduct, C-peptide. Research indicates the potential for MLR-1023 to induce proliferation of a patient’s remaining beta cells. Adhera, alongside independent researchers, hypothesize that if the beta cell mass can be expanded in the C-peptide positive patient population, it may be possible to either reduce or eliminate the exogenous insulin requirement. In addition to the U of A trial, the company is pleased to inform shareholders that progress is being made towards filing an application to uplist to the NASDAQ, a milestone that should yield additional liquidity and allow the Company to secure financing for clinical trials for both MLR-1019 for Parkinson’s Disease and MLR-1023 for Type 1 Diabetes. 공시 • Jul 20
Adhera Therapeutics, Inc. (OTCPK:ATRX) enter into letter of intent to acquire CD71-Targeted Cancer Therapy Paclitaxel Gallium Transferrin from Bio Innovation Group. Adhera Therapeutics, Inc. (OTCPK:ATRX) enter into letter of intent to acquire CD71-Targeted Cancer Therapy Paclitaxel Gallium Transferrin from Bio Innovation Group on July 19, 2022. While best efforts are anticipated to advance the Heads of Terms agreement to an executed definitive agreement pursuant to which Adhera will acquire PGT, no assurances of such a development are expressed, implied, or guaranteed. 공시 • Jun 29
Adhera Therapeutics, Inc., Annual General Meeting, Aug 18, 2022 Adhera Therapeutics, Inc., Annual General Meeting, Aug 18, 2022, at 10:00 US Eastern Standard Time. Agenda: To elect four directors for a one-year term expiring at the next annual meeting of stockholders; to ratify the selection of Salberg & Company, P.A. as the Company’s independent registered public accounting firm for the year ending December 31, 2022; to approve amendment(s) to the Company's Certificate of Incorporation to effect one or more reverse stock splits of the Company's issued and outstanding shares of common stock, par value USD 0.006 per share, at a ratio to be determined in the discretion of the Company's Board of Directors within a range of one-for-two through one-for-200, provided that in no event shall such amendments collectively exceed a reverse stock split ratio of one-for-200; and to consider other matters. 공시 • Apr 03
Adhera Therapeutics, Inc. announced delayed annual 10-K filing On 04/01/2022, Adhera Therapeutics, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. 공시 • Nov 24
Adhera Therapeutics, Inc. Contemplates Bankruptcy Adhera Therapeutics, Inc. is contemplating filing for bankruptcy, as of November 22, 2021. According to SEC filing, Company is in financial distress due to substantial unpaid debt. Adhera Therapeutics is continuing to work with its advisors to restructure the company and to identify potential strategic transactions, including the Melior transaction to enhance the value of the company. Because of the substantial unpaid debt, if the company does not raise substantial additional capital in the immediate future, it is likely that the company will discontinue all operations and seek bankruptcy protection. 공시 • Sep 15
Adhera Therapeutics, Inc. Provides Insight on Corporate Strategy, Development of Parkinson’s Disease and Type 1 Diabetes Drugs Adhera Therapeutics, Inc. provided shareholders an update on corporate strategy and planned clinical development of MLR-1019 (armesocarb) and MLR-1023 (tolimidone). On July 29, 2021 and August 24, 2021, respectively, the Company announced executing exclusive license agreements for MLR-1019 for Parkinson’s disease (PD) and MLR-1023 for Type 1 diabetes. Adhera will develop MLR-1019 as a new class of drug for PD and, to the best of the Company’s knowledge, as the only drug candidate designed to address both movement and non-movement symptoms of PD. Armesocarb is the active enantiomer in mesocarb, a drug marketed in Europe for 37 years for various psychiatric and central nervous system indications. Based upon previous work conducted by licensing partner Melior Pharmaceuticals II, LLC (“Melior 2”), a clear understanding of MLR-1019’s mechanism of action, abundant pre-clinical research and decades of clinical data on mesocarb, which is chemically related to armesocarb, Adhera intends to initiate a Phase 2a clinical trial in an Eastern European jurisdiction where mesocarb still has marketing registration. The Company will undertake a parallel process in the U.S. with Investigational New Drug (IND)-enabling studies. Adhera believes that the comprehensive historical data in combination with new data from clinical trials in Europe will facilitate an accelerated development pathway in the U.S. MLR-1023, a lyn kinase activator, has demonstrated exceptional clinical safety and tolerability in over 700 patients in Phase 2a and Phase 2b clinical trials in patients with Type 2 diabetes. The Company will work under the IND of license partner Melior Pharmaceuticals I, Inc. (“Melior 1”) to continue clinical development of MLR-1023, with a transition to Type 1 diabetes as the target indication. The decision to focus on Type 1 diabetes was supported by multiple factors, including: Compelling work by an independent investigator in Canada demonstrating the ability of MLR-1023 to confer unique benefits to pancreatic beta cell (insulin producing cells) in models of Type 1 diabetes. Longer period of market exclusivity for Type 1 diabetes compared to Type 2 diabetes. Blue sky opportunity for an oral Type 1 diabetes drug (market for oral Type 2 diabetes drugs is already crowded). Cost to market is substantially lower for Type 1 diabetes compared to Type 2 diabetes. 공시 • Aug 18
Adhera Therapeutics, Inc. announced delayed 10-Q filing On 08/17/2021, Adhera Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. 공시 • May 25
Adhera Therapeutics, Inc. Contemplates Bankruptcy Adhera Therapeutics, Inc. is contemplating filing for bankruptcy, as of May 24, 2021. According to SEC filing, Company said that its has been working with its advisors to restructure the company with all the resources available. Adhera is identifying potential strategic transactions to enhance the value of the company as such opportunities arise, including potential transactions and capital raising initiatives involving the assets relating to legacy RNA interference programs, as well as business combination transactions with operating companies. There can be no assurance that the company will be successful at identifying any such transactions, that it will continue to have sufficient resources to actively attempt to identify such transactions, or that such transactions will be available upon terms acceptable to the company or at all. If Adhera do not complete any significant strategic transactions, or raise substantial additional capital, in the immediate future, it is likely that the company will discontinue all operations and seek bankruptcy protection. 공시 • May 18
Adhera Therapeutics, Inc. announced delayed 10-Q filing On 05/17/2021, Adhera Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. 공시 • Apr 03
Adhera Therapeutics, Inc. announced delayed annual 10-K filing On 04/01/2021, Adhera Therapeutics, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. 공시 • Nov 19
Adhera Therapeutics, Inc. Contemplates Bankruptcy Adhera Therapeutics, Inc. is contemplating filing for bankruptcy, as of November 18, 2020. According to SEC filing, Company said that it has been working with its advisors to restructure the company and to identify potential strategic transactions to enhance the value of the company as such opportunities arise, including potential transactions and capital raising initiatives involving the assets relating to legacy RNA interference programs, as well as business combination transactions with operating companies. If the Company does not complete any significant strategic transactions, or raise substantial additional capital, in the immediate future, it is likely that the Company will discontinue all operations and seek bankruptcy protection. 공시 • Nov 18
Adhera Therapeutics, Inc. announced delayed 10-Q filing On 11/16/2020, Adhera Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. 공시 • Aug 15
Adhera Therapeutics, Inc. announced delayed 10-Q filing On 08/14/2020, Adhera Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. 공시 • Jul 17
Adhera Therapeutics, Inc. Appoints Andrew Kucharchuk as the Chief Executive Officer On July 7, 2020, the Board of Directors of Adhera Therapeutics, Inc. engaged Mr. Andrew Kucharchuk to serve as the Chief Executive Officer of the Company effective immediately. Mr. Kucharchuk, previously served as President and Chief Financial Officer of OncBioMune Pharmaceuticals, Inc. from February 2016 until June 2020. 공시 • Jul 07
Adhera Therapeutics, Inc. May File for Bankruptcy Adhera Therapeutics, Inc. may file for bankruptcy, as of July 6, 2020. The company may file for bankruptcy if it fails to get the required financing.